

CANCER – BREAKING BAD

This program might have changes until the very last moment.

Latest news and updates are always available in BioCity Turku web page

<https://biocityturku.fi/biocity-symposium/>

THURSDAY, AUGUST 19th 2021

- 10.00 **Carl G. Gahmberg**, Chancellor of Åbo Akademi University
Opening words
Awarding the Elias Tillandz prize for the best publication in BioCity Turku 2020
Vesa Kataja, Scientific Advisory Board Chair of Finnish Cancer Institute
Awarding the Eero Saksela Prize for outstanding recent post-doctoral cancer researcher

SESSION I Therapy stratification (chairs: Klaus Elenius, Kari Kurppa)

- 10.30 **Edwin Cuppen**, Hartwig Medical Foundation, and UMC Utrecht, The Netherlands
Clinical grade Whole Genome Sequencing for diagnostics and trial support in the Netherlands
- 11.15 Break from the scientific program
- 11.45 **Gong-Hong Wei**, University of Oulu, and Shanghai Medical College of Fudan University, China
Epigenome and cistrome-based prostate cancer post-GWAS analysis
- 12.30 **Janne Lehtiö**, Karolinska Institutet, Stockholm, Sweden
Proteogenomics connecting lung cancer tumor genome to molecular and immune phenotype
- 13.15 **Srikar Nagelli**, Turku Bioscience Centre, University of Turku, Finland
A novel personalized patient stratification strategy for better clinical management of basal-like breast cancer (BLBC)
- 13.30 Break from the scientific program

SESSION II Pathway directed therapies (chairs: Heikki Minn, Maria Sundvall)

- 15.00 Winner of the Eero Saksela Prize
- 15.15 **Sakari Vanharanta**, MRC Cancer Unit, University of Cambridge, UK
Deconstructing tissue-specific mechanisms of carcinogenesis
- 16.00 **Marja Jäättelä**, University of Copenhagen, Denmark
Targeting cancer through lysosomes
- 16.45 **Kimmo Kettunen**, University of Turku, Finland
About steroidomics of Bladder Cancer
- 17.00 **Mauro Scaravilli**, University of Eastern Finland, Finland
RNA-binding protein FUS/TLS regulates oncogenic gene fusion products in prostate cancer
- 17.15 **Stephen J. Elledge**, Harvard Medical School, USA
Countering immune evasion: one step backward, two steps forward
- 18.00 First symposium day ends in BioCity

FRIDAY, AUGUST 20th 2021

SESSION III Tumor microenvironment (chairs: Emilia Peuhu, Maija Hollmén)

- 10.00 **Leila Akkari**, Netherlands Cancer Institute, The Netherlands
Rewiring tumor-associated macrophage heterogeneity in cancer
- 10.45 **Marjaana Parikainen**, Åbo Akademi University, Finland
The Notch ligand Jagged1 regulates growth, invasion, and extracellular matrix production of breast cancer cells
- 11.00 **Sanni Alve**, University of Helsinki, Finland
Melanoma induced pro-metastatic changes in lymphatic endothelial cells
- 11.15 Break from the scientific program
- 11.45 **Johanna Ivaska**, K. Albin Johansson -professor, University of Turku, Finland
Tumor – stroma interactions in cancer progression

SESSION IV Cancer – paradigm lost (chairs: Sirpa Jalkanen, Tapio Lönnberg)

- 12.30 **Carl-Gustav A. Stenvall**, Åbo Akademi University, Finland
Intestinal keratin 8 safeguards against colonic tumorigenesis and pathologies
- 12.45 **Anna Aakula**, Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland
Altered PP2A regulation of the epigenetic machinery in cancer
- 13.00 **Vera Gorbunova**, University of Rochester, US
Mechanisms of cancer resistance: lessons from long-lived mammals
- 13.45 Break from the scientific program
- 15.00 **Robert A. Gatenby**, Moffitt Cancer Center and Research Institute, US
Integrating evolutionary dynamics into clinical cancer therapy

PANEL DISCUSSION (chairs: Jukka Westermarck, Anna Aakula)

- 15.45 American Association for Cancer Research, AACR:
I-Mei Siu, Senior editor of Cancer Discovery
Marlowe Tessmer, Executive Editor of Clinical Cancer Research
Harmony Turk, Executive Editor of Cancer Research
- 16.45 **Jyrki Heino**, BioCity Turku
Closing remarks
- 17.00 Second symposium day ends in BioCity